시장보고서
상품코드
1671863

재조합 백신 시장 : 유형별, 적응증별, 최종사용자별, 유통 채널별, 지역별

Recombinant Vaccine Market, By Type, By Indication, By End User, By Distribution Channel, By Geography

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

재조합 백신 세계 시장은 2025년에 125억 2,000만 달러로 추정되며, 2025년부터 2032년까지 CAGR 11.7%로 성장하여 2032년에는 271억 7,000만 달러에 달할 것으로 예상됩니다.

보고서 범위 보고서 상세
기준 연도 2024년 2025년 시장 규모 125억 2,000만 달러
실적 데이터 2020-2024년 예측 기간 2025-2032년
예측 기간 : 2025-2032년 CAGR 11.70% 2032년 가치 예측 271억 7,000만 달러
그림. 재조합 백신 시장 점유율(%), 지역별, 2025년
Recombinant Vaccine Market-IMG1

재조합 백신은 백신 항원을 암호화하는 유전자를 효모, 박테리아, 바이러스 등 다른 생물의 유전자와 결합하여 재조합 DNA 기술을 이용하여 개발됩니다. 재조합 유전자를 숙주 세포에 도입하고 이를 대형 발효기에서 배양하여 항원 단백질을 생산합니다. 재조합 기술은 계절이나 질병 유행에 관계없이 정확하게 제어된 조건에서 항원을 대량 생산할 수 있기 때문에 기존 백신 생산의 많은 제약을 극복하고 있습니다. 낮은 생산 비용, 높은 수율, 확장성 등의 장점으로 인해 세계 재조합 백신 시장은 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다.

시장 역학:

세계 재조합 백신 시장은 감염성 질환의 증가, 백신 접종에 대한 인식 증가, 재조합 DNA 생산 기술의 기술적 진보 등의 요인으로 인해 견조한 성장이 예상됩니다. 그러나 높은 개발 비용과 엄격한 규제 프레임워크가 시장 성장에 걸림돌이 될 것으로 예상됩니다. 반면, 미개발 인구가 많은 신흥국에는 제조업체에게 유리한 비즈니스 기회가 있습니다. 시장 개발 기업들은 연구개발에 투자하여 새로운 질병 적응증에 대한 백신과 건강검진 시 추가 접종 기회를 제공하고 환자의 순응도를 향상시키는 혼합 백신을 개발하고 있습니다.

본 조사의 주요 특징

세계의 재조합 백신 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 조사하여 전해드립니다.

또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.

또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.

이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 재조합 백신 시장의 주요 기업을 프로파일링합니다.

주요 기업으로는 Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., Inovio Pharmaceuticals, Inc. 등이 있습니다.

이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.

재조합 백신 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.

이해관계자들은 세계 재조합 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

  • 조사 목적
  • 가정
  • 약어

제2장 시장 전망

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
  • 영향 분석
  • 주요 발전
  • 규제 시나리오
  • 제품 발매/승인
  • PEST 분석
  • PORTER의 분석
  • 인수합병 시나리오
  • 업계 동향

제4장 세계의 재조합 백신 시장, 유형별, 2020-2032년

  • 약독화 재조합 백신
  • 벡터 재조합 백신
  • 서브유닛 재조합 백신

제5장 세계의 재조합 백신 시장, 적응증별, 2020-2032년

  • 인유두종바이러스(HPV)
  • 수막염균
  • B형 간염
  • 인플루엔자
  • 로타바이러스
  • 대상포진
  • 기타

제6장 세계의 재조합 백신 시장, 최종사용자별, 2020-2032년

  • 소아
  • 성인
  • 노인

제7장 세계의 재조합 백신 시장, 유통 채널별, 2020-2032년

  • 병원 및 약국
  • 정부 공급업체
  • 백신 접종 센터

제8장 세계의 재조합 백신 시장, 지역별, 2020-2032년

  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제9장 경쟁 구도

  • Merck & Co., Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Novavax, Inc.
  • AstraZeneca Plc.
  • Dynavax Technologies Corporation
  • Serum Institute of India Pvt. Ltd.
  • Emergent BioSolutions Inc.
  • Bharat Biotech
  • Protein Sciences Corporation
  • VBI Vaccines Inc.
  • Inovio Pharmaceuticals, Inc.

제10장 애널리스트의 추천사항

  • Wheel of Fortune
  • 애널리스트의 견해
  • Coherent Opportunity Map

제11장 참고문헌과 조사 방법

  • 참고문헌
  • 조사 방법
  • 출판사 소개
ksm 25.04.10

Global Recombinant Vaccine Market is estimated to be valued at US$ 12.52 Bn in 2025 and is expected to reach US$ 27.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: US$ 12.52 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 11.70% 2032 Value Projection: US$ 27.17 Bn
Figure. Recombinant Vaccine Market Share (%), By Region 2025
Recombinant Vaccine Market - IMG1

Recombinant vaccines are developed using recombinant DNA technology by combining genes that code for vaccine antigens with the genes of another organism like yeast, bacteria, or viruses. The recombinant genes are then transferred into host cells which are then cultured in large fermenters to produce antigen proteins. Recombinant technology overcomes many limitations of conventional vaccine production as antigens can be mass produced in precisely controlled conditions regardless of season or disease outbreak. With benefits of low production cost, high yield and scalability, the global recombinant vaccine market is expected to experience significant growth over the forecast period.

Market Dynamics:

The global recombinant vaccine market is projected to witness robust growth attributable to factors such as increasing prevalence of infectious diseases, rising awareness about vaccination, and technological advancement in recombinant DNA production techniques. However, high development costs and stringent regulatory framework are expected to impede the market growth. On the other hand, emerging economies with large untapped populations present lucrative opportunities for manufacturers. Market players are investing in R&D to develop vaccines for new disease indications as well as combination vaccines which provide an opportunity for additional vaccination during well-child visits, thereby improving patient compliance.

Key Features of the Study:

This report provides in-depth analysis of the global recombinant vaccine market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global recombinant vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., and Inovio Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global recombinant vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant vaccine market

Market Segmentation

  • By Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Attenuated Recombinant Vaccines
    • Vector Recombinant Vaccines
    • Subunit Recombinant Vaccines
  • By Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Human Papillomavirus (HPV)
    • Meningococcal
    • Hepatitis B
    • Influenza
    • Rotavirus
    • Herpes Zoster
    • Others
  • By End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital & Retail Pharmacies
    • Government Suppliers
    • Vaccination Centers
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Pfizer Inc.
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Novavax, Inc.
    • AstraZeneca Plc.
    • Dynavax Technologies Corporation
    • Serum Institute of India Pvt. Ltd.
    • Emergent BioSolutions Inc.
    • Bharat Biotech
    • Protein Sciences Corporation
    • VBI Vaccines Inc.
    • Inovio Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Recombinant Vaccine Market, By Type
    • Global Recombinant Vaccine Market, By Indication
    • Global Recombinant Vaccine Market, By End User
    • Global Recombinant Vaccine Market, By Distribution Channel
    • Global Recombinant Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Recombinant Vaccine Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Attenuated Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Vector Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subunit Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Recombinant Vaccine Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Human Papillomavirus (HPV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Meningococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rotavirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Herpes Zoster
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Recombinant Vaccine Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Recombinant Vaccine Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital & Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Government Suppliers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Vaccination Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Recombinant Vaccine Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novavax, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dynavax Technologies Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Serum Institute of India Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emergent BioSolutions Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bharat Biotech
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Protein Sciences Corporation
  • VBI Vaccines Inc.
  • Inovio Pharmaceuticals, Inc.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제